IRadimed Corporation
NASDAQ:IRMDMedical - Devices
+$0.67 today
- Market cap
- $1.05B
- Beta
- 0.92
- P/E (TTM)
- 49.7
- EPS (TTM)
- $1.85
- Dividend yield
- 1.35%
Volume 0.08M
Average 0.12M
IRMD Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
IRadimed CorporationNASDAQ: IRMD
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization growth accelerates
Q1 FY2026 depreciation & amortization of $455K rose 134.4% year over year, ahead of the +81.6% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 19.5% from the prior quarter. Over 3 fiscal years it compounded at +20.2% a year.
Context
- Depreciation & amortization amounted to 1.4% of revenue in FY2025, up 0.3 pp from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +134.4% holds above the trailing-twelve-month pace of +81.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 1.17M USD
- Year-over-year change
- +42.6%
- 4-year CAGR
- -4.6%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.17M | +42.6% |
| FY2024 | 2024-12-31 | 817.66K | +6.9% |
| FY2023 | 2023-12-31 | 765.18K | +14.1% |
| FY2022 | 2022-12-31 | 670.67K | -52.3% |
| FY2021 | 2021-12-31 | 1.41M | — |
Depreciation & Amortization vs competitors
How IRMD compares with its peers on the latest reported figures
- IRMD's LTM Mar 2026 depreciation & amortization of $1.43M is the 9th largest of the 11 companies compared; the peer median is $49.83M.
- Its year-over-year change of +81.6% is the 2nd highest of 11, against a peer median of +2.8%.
- Depreciation & amortization amounts to 1.7% of revenue for IRMD, versus a peer median of 6.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
CTEVClaritev Corporation | LTM Mar 2026 | $448.02M | +1.9% | +2.3% | 45.8% |
| LTM Apr 2026 | $416.38M | +10.6% | +2.8% | 14.6% | |
| LTM Mar 2026 | $153.07M | +3.8% | +8.7% | 9.3% | |
| LTM Mar 2026 | $90.34M | -5.7% | -5.5% | 15.5% | |
| LTM Mar 2026 | $82.56M | +10.8% | +16.3% | 10.5% | |
| LTM Mar 2026 | $17.11M | -1.1% | -1.2% | 1.7% | |
| LTM Mar 2026 | $16.5M | +94.2% | +54.4% | 4.2% | |
| LTM Sep 2026 | $8.91M | +19.5% | +19.1% | 3.3% | |
| LTM Mar 2026 | $1.43M | +81.6% | +20.2% | 1.7% | |
| LTM Mar 2026 | $835.37K | -92.0% | +3.3% | 0.4% | |
| LTM Mar 2026 | $696K | -5.6% | +0.7% | 0.2% | |
| Peer median (excluding IRMD) | $49.83M | +2.8% | +3.1% | 6.8% | |
Competitors are the stored peer set for IRMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 9.33M | 12.83M | 17.19M | 19.23M | 22.48M |
| Depreciation & Amortization | 1.41M | 670.67K | 765.18K | 817.66K | 1.17M |
| Deferred Income Tax | 523.61K | 57.1K | (1.17M) | (697.65K) | 0 |
| Stock-Based Compensation | 1.46M | 1.39M | 2.19M | 2.52M | 2.92M |
| Change in Working Capital | (1.58M) | (5.06M) | (5.91M) | 3.75M | (4.35M) |
| Accounts Receivables | (575.54K) | (8.24M) | 841.91K | 1.76M | (3.03M) |
| Inventory | (393.32K) | (1.31M) | (7.47M) | 3.13M | (1.38M) |
| Accounts Payables | 30.41K | 1.12M | (216.44K) | (861.62K) | (76K) |
| Other Working Capital | (637.72K) | 3.37M | 932.43K | (277.58K) | 135K |
| Other Non-Cash Items | 119.04K | 148.74K | 402.32K | (3.02K) | 2.73M |
| Operating Cash Flow | 11.26M | 10.04M | 13.47M | 25.62M | 24.95M |
| Capital Expenditures | (741.76K) | (1.87M) | (8.01M) | (8.01M) | (7.77M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 1.39M | 500K | 0 | 0 | 0 |
| Other Investing Activities | (259.43K) | (1.05M) | (566.66K) | (811.75K) | (656K) |
| Investing Cash Flow | 648.24K | (1.37M) | (8.01M) | (8.82M) | (8.42M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 0 | 0 | 29.62K | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | (12.56M) | (13.22M) | (13.68M) | (15.04M) |
| Other Financing Activities | 24.43K | (147.27K) | (433.6K) | (688.16K) | (2.56M) |
| Financing Cash Flow | 24.43K | (12.71M) | (13.66M) | (14.34M) | (17.6M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 11.93M | (4.04M) | (8.2M) | 2.47M | (1.08M) |
| Free Cash Flow | 10.52M | 8.17M | 5.46M | 17.62M | 17.18M |
IRadimed Corporation
NASDAQ:IRMD
Intrinsic Alpha fair value
Locked
Current Price
$82.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.